Hetero Announces Interim Clinical Results from Phase III Clinical Trials of Molnupiravir conducted in India

Hetero, Press Release, Jul 2021
Early treatmentRCT ยท 741 patients ยท India
Molnupiravir for COVID-19
Hetero Press Release ยท July 2021
Outcome
Improvement
Relative Risk ยท 95% CI
00.511.52+
โ† Molnupiravir
reduces risk
Molnupiravir
increases risk โ†’
Lower hospitalization and faster recovery
p = 0.0027 (hospitalization) and p = 0.0001 (recovery)
Interim results for CTRI/2021/05/033739, showing lower mortality and faster recovery.
Potential risks of molnupiravir include the creation of dangerous variants, and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity1-15. Multiple analyses have identified variants potentially created by molnupiravir16-20. Studies show significantly increased risk of acute kidney injury21, cardiovascular toxocity22, and neurological symptoms21. Treatment may increase viral rebound23,24.
OutcomeImprovementEffect ยท pTreatmentControl
risk of hospitalization 69.6% lower ยท RR 0.30 ยท p = 0.003** 69.6% lowerRR 0.30p = 0.003** 7 of 371 (1.9%) 23 of 370 (6.2%) treatment 7 of 371 (1.9%), control 23 of 370 (6.2%)NNT 23
recovery time 33.3% lower ยท relative time 0.67 ยท p < 0.001*** 33.3% lowerrelative time 0.67p < 0.001*** 371 370 treatment 371, control 370

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates. ** p < 0.01   *** p < 0.001

Hetero et al., 9 Jul 2021, Randomized Controlled Trial, India, peer-reviewed, 1 author, licensee.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2026 India Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Brazil France Italy Canada Pakistan Spain Vietnam Japan Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Poland Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Dominican Republic Bolivia Cรดte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia Benin Burundi Cameroon CAR India favored low-cost treatments.The average efficacy of treatments was moderate.Low-cost treatments improve early treatment, andprovide complementary/synergistic benefits. More effective More expensive 75% 50% 25% โ‰ค0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2026 India Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Brazil France Italy Canada Pakistan Spain Vietnam Japan Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Dominican Rep. Bolivia Cรดte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia Benin Burundi CAR Syria India favored low-cost treatments.The average efficacy was moderate.Low-cost protocols improve early treatment,and add complementary/synergistic benefits. More effective More expensive 75% 50% 25% โ‰ค0%
Hetero Announces Interim Clinical Results from Phase III Clinical Trials of Molnupiravir conducted in India
~ Phase 3 Trial Demonstrates Statistically Significant fewer hospital admissions, Faster Time to Clinical Improvement and early negative SARS CoV-2 RT PCR with Molnupiravir Treatment in Mild COVID 19 Patients Compared to Standard of Care alone~ ~ Hetero has approached the Drug Controller General of India (DCGI) to seek Emergency Use Authorization for Molnupiravir in India ~ India, Hyderabad, 9 th July 2021: Hetero, a globally renowned vertically integrated pharmaceutical organization, today announced the interim clinical results from Phase III Clinical trials of Molnupiravir in mild Covid-19 patients conducted across multiple COVID-19 dedicated hospital sites across India. In April this year, Hetero had entered into a non-exclusive licensing agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE: MRK), to manufacture and supply Molnupiravir in India and over 100 low and middle-income countries (LMICs). Molnupiravir is an investigational, orally administered form of a potent ribonucleoside analog, being developed globally by MSD, that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19 with demonstrated activity against SARS-CoV-2 in human airway epithelial cell cultures and potential to completely eliminate SARS CoV-2 from the body within 5 days. Hetero had commenced a phase-III, comparative, randomized, multicenter clinical trial on mild Covid-19 patients (N=1218). These clinical trials were aimed at evaluating the efficacy and safety of Molnupiravir plus standard of care (test arm) versus standard of care alone (control